SpringerPlus

Table 1 Patient characteristics

From: Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy

Sex	Male/female	72/18
Type of malignancy	Small-cell lung cancer	10
Type of malignancy	Non-small-cell lung cancer	80
Performance status	0	35
	1	50
	2	5
Median age (range), years		69 (38–82)
Chemotherapy regimen
	Carboplatin + paclitaxel	35
	Carboplatin + pemetrexed	24
	Carboplatin + TS-1	13
	Carboplatin + etoposide	12
	Carboplatin + docetaxel	6

Back to article page